Table 1.

Overview of included trials with the SQ HDM SLIT-tablet

Trial	Treatment	Population	Rhinitis	Asthma
MT-04 (phase III) EudraCT: 2010-018621-19 [24]	6 or 12 SQ-HDM or placebo, 13–19 months of treatment	834 adults	HDM allergic rhinitis, no requirements for severity or medication use	HDM allergic asthma not well controlled by ICS corresponding to the doses used at GINA medication steps 2–4
MT-06 (phase III) EudraCT: 2011-002277-38 [25]	6 or 12 SQ-HDM or placebo, 1 year of treatment	992 adults	Moderate-to-severe HDM allergic rhinitis with a high level of symptoms and impaired quality of life despite frequent medication use	Mild asthma controlled by ICS (GINA medication steps 1–2) allowed but not required

HDM, house dust mite; ICS, inhaled corticosteroids; GINA, Global Initiative for Asthma.